By Misty Long, ARRT, RT (R)(N), Siemens Healthineers Molecular Imaging, Knoxville, Tennessee, USA and
Steve Wozniak, BS, CNMT, PET, 210 PET Imaging, Cary, North Carolina, USA
Data and images courtesy of 210 PET Imaging, Cary, North Carolina, USA
18F-FES PET/CT distinction of ER-positive lesions in a patient with metastatic breast cancer
2024-07-09
An approximately 65-year-old female with metastatic breast cancer underwent sequential 18F-FES and 18F-FDG PET/CT imaging on Biograph Vision™ PET/CT to assess the extent of disease and estrogen-receptor (ER) status. This case demonstrates the utility of 18F-FES PET/CT in the evaluation of metastatic disease burden to help inform therapy treatment planning.
Clinical case study